Viewing Study NCT00251394

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:00 AM
Ignite Modification Date: 2026-02-27 @ 9:05 AM
Study NCT ID: NCT00251394
Status: COMPLETED
Last Update Posted: 2010-01-29
First Post: 2005-11-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma
Sponsor: Dana-Farber Cancer Institute
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Hodgkin's Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None B-Cell follicular non-Hodgkin's lymphoma View
None Rituxan View
None Rituximab View
None 1018 ISS View
None CD 20 + View